Olanzapine Mylan (Olanzapine)

Olanzapine Mylan is an atypical antipsychotic that acts on dopamine and serotonin pathways to treat several psychiatric conditions.

• Schizophrenia: Reduces hallucinations, delusions and thought disorder.
• Bipolar I disorder (manic episodes): Helps control mood swings and acute manic symptoms.
• Bipolar depression: Provides adjunctive treatment to improve depressive symptoms.
• Schizoaffective disorder: Alleviates both psychotic and mood components.
• Maintenance therapy: Helps prevent relapse of psychotic episodes.

• Olanzapine works primarily by antagonizing dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain. This dual blockade modulates neurotransmission, decreasing dopaminergic overactivity and normalising serotonergic tone, which together contribute to its antipsychotic and mood‑stabilising effects.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Weight gain: Often noticeable within the first weeks of therapy.
• Sedation: Drowsiness or feeling of being overly relaxed.
• Dry mouth: Reduced salivation leading to a dry oral cavity.
• Constipation: Slowed gastrointestinal motility.
• Elevated triglycerides: Increases in blood lipid levels.
• Increased appetite: May contribute to weight gain.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: Involuntary, repetitive movements, especially of the face.
• Hyperglycaemia/diabetes mellitus: Significant rise in blood glucose levels.
• Seizures: May provoke convulsive episodes in susceptible individuals.
• Agranulocytosis: Marked reduction in white‑blood cell count.
• Severe hypotension: Marked drop in blood pressure, especially when standing.

When prescribing Olanzapine Mylan, clinicians should consider several safety aspects.

• Monitor metabolic parameters: Regularly check weight, fasting glucose and lipid profile.
• Assess for cardiovascular risk: Evaluate blood pressure and heart rate regularly.
• Screen for movement disorders: Observe for early signs of tardive dyskinesia.
• Use caution in hepatic impairment: Dose adjustments may be required.
• Avoid abrupt discontinuation: Gradual tapering reduces relapse risk.
• Store at below 25°C: Keep in the original container, protect from moisture and light.

Olanzapine can interact with a variety of medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Increase olanzapine plasma levels.
• CNS depressants (e.g., benzodiazepines, opio opio");

Moderate  Sorry ");